Helix BioPharma Corp. Appoints New Independent Chair Of The Board

(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Yvon Bastien as the new Chair of the board effective July 17, 2014. Mr. Bastien has served as an independent director of the Company since December 2013 and remains the Chair of the board’s Governance & Compensation Committee. Mr. Robert Verhagen has served as Interim Chair since December 2013 and remains a Director of the Company and President and CEO.